Astraveus

The company's business model revolves around the use of its proprietary technology to miniaturize and optimize cellular therapies and their manufacturing process. By leveraging the ability of therapeutic cells to multiply in the patient's body, Astraveus can use small amounts of resources without compromising the efficacy of the therapy. This approach not only reduces costs but also minimizes the environmental impact of these therapies.

Astraveus' Lakhesys™ platform is unique in its use of microfluidic bioprocessors, which mimic organ perfusion and accelerate the molecular exchanges needed to transform cells into therapeutic agents. Once the process is optimized, Lakhesys™ can produce up to 100 minibatches simultaneously in a conventional size manufacturing room, resulting in higher quality products at a lower cost and with reduced environmental impact.

Astraveus' clients are likely to be healthcare providers and institutions seeking to provide CGT therapies to their patients. The company operates in the global CGT manufacturing market, which is expected to grow significantly in the coming years. Astraveus has received funding from the European Union's Horizon 2020 research and innovation program, indicating strong support and belief in its potential.